stroke-recovery
(4)
Enspire DBS Therapy, Inc.
Enspire DBS Therapy is a Cleveland-based, clinical-stage medical device company commercializing deep brain stimulation (DBS) paired with physical rehabilitation to restore arm and hand function in people living with chronic impairment after a stroke. Spun out of Cleveland Clinic in 2010, the company builds on more than a decade of research targeting the brain's dentate nucleus to re-establish neurological input during rehab. Its DBS-plus-rehab approach showed encouraging results in the first-in-human EDEN trial published in Nature Medicine, and Enspire is now running RESTORE, a multicenter pivotal study aimed at FDA marketing authorization.
Scott Kokones
Scott Kokones is co-founder and CEO of Enspire DBS Therapy, a Cleveland Clinic portfolio company building an implantable deep brain stimulation system paired with physical rehab to restore arm function in stroke survivors. He is running the RESTORE pivotal trial after the EDEN proof-of-concept study, having raised $27.9M total including a $17.6M Series B in 2023 and a $10.3M Series B1 in January 2026. Alongside Enspire he is a general partner at Guide Medical Ventures and a co-founder of Qr8 Health and CardioSolv Ablation Technologies. His earlier career runs through Intelect Medical, Boston Scientific, Enpath Medical, and Medtronic.
Constant Therapy
Constant Therapy is a Boston-area digital health company that turns speech, language, and cognitive rehabilitation into an AI-personalized app. Spun out of Boston University's Aphasia Research Laboratory in 2012, its platform delivers more than 100,000 evidence-based exercises across 80-plus task categories to people recovering from stroke, traumatic brain injury, aphasia, dementia, and other neurological conditions - and to the clinicians who treat them. A patented NeuroPerformance Engine adapts each session to the individual, extending therapy beyond the clinic and into daily home practice.
REEV
REEV is a medical robotics company building AI-powered wearable robotics to restore everyday mobility for people with neurological gait disorders after stroke, multiple sclerosis or paraplegia. Its flagship DREEVEN is a lightweight (about 3kg) motorized knee orthosis driven by electro-hydraulic actuation and real-time gait sensing, paired with REEV SENSE, an IMU wearable that turns a person's walking pattern into clinical-grade gait reports. Founded in 2021 and split between Boston and Toulouse, REEV raised $9.2M in February 2025 to finalize DREEVEN, run a clinical study at Boston University and prepare for FDA trials.